-
EP3922279
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3922279
| EP3922279 - DRUG DELIVERY COMPOSITIONS AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 02.09.2022 Database last updated on 03.06.2024 | |
| Former | Request for examination was made Status updated on 17.06.2022 | ||
| Former | The application has been published Status updated on 12.11.2021 | Most recent event Tooltip | 23.03.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Dana Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, Massachusetts 02215-5450 / US | [2021/50] | Inventor(s) | 01 /
GOLDBERG, Michael Solomon Brookline, 02446 / US | 02 /
PARK, Chun Gwon Boston, 02115 / US | [2021/50] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2021/50] | HGF 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 21171683.2 | 30.08.2017 | [2021/50] | Priority number, date | US201662381456P | 30.08.2016 Original published format: US 201662381456 P | US201762486814P | 18.04.2017 Original published format: US 201762486814 P | US201762501464P | 04.05.2017 Original published format: US 201762501464 P | [2021/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3922279 | Date: | 15.12.2021 | Language: | EN | [2021/50] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 06.10.2021 | Classification | IPC: | A61L26/00, A61K9/06, A61K47/36, A61K38/17, A61K38/19, A61K39/395 | [2021/50] | CPC: |
C07K16/2818 (EP,US);
A61K9/0024 (EP,KR,US);
A61K31/415 (KR);
A61K31/444 (EP,US);
A61K31/4745 (EP,US);
A61K31/635 (EP,US);
A61K38/1793 (US);
A61K38/19 (EP,KR,US);
A61K38/2086 (US);
A61K38/21 (KR);
A61K39/395 (KR);
A61K39/39541 (EP,US);
A61K39/3955 (US);
A61K45/06 (EP,KR,US);
A61K47/36 (EP,KR,US);
A61K9/0019 (US);
A61K9/06 (EP,KR,US);
A61P35/00 (KR);
A61P35/04 (EP,US);
C07H21/04 (EP,US);
C07K16/2878 (EP,US);
C07K16/2896 (US);
C07K16/30 (US);
A61K2039/505 (EP,KR,US);
A61K2300/00 (KR);
A61K35/17 (EP,KR,US);
A61L27/52 (US);
C07K2317/75 (EP,US)
(-)
| C-Set: |
A61K31/444, A61K2300/00 (EP,US);
A61K31/4745, A61K2300/00 (US,EP);
A61K31/635, A61K2300/00 (US,EP);
A61K38/19, A61K2300/00 (US,EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/29] |
| Former [2021/50] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | ARZNEIMITTELABGABEZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON | [2021/50] | English: | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | [2021/50] | French: | COMPOSITIONS POUR L'ADMINISTRATION DE MÉDICAMENTS ET LEURS UTILISATIONS | [2021/50] | Examination procedure | 13.06.2022 | Examination requested [2022/29] | 13.06.2022 | Date on which the examining division has become responsible | 06.09.2022 | Despatch of a communication from the examining division (Time limit: M06) | 15.03.2023 | Observations by third parties | 04.05.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 14.07.2023 | Reply to a communication from the examining division | 28.07.2023 | Despatch of a communication from the examining division (Time limit: M06) | 07.02.2024 | Reply to a communication from the examining division | 22.03.2024 | Despatch of a communication from the examining division (Time limit: M04) | Parent application(s) Tooltip | EP17765524.8 / EP3506884 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 14.07.2023 | Request for further processing filed | 14.07.2023 | Full payment received (date of receipt of payment) Request granted | 19.07.2023 | Decision despatched | Fees paid | Renewal fee | 12.08.2021 | Renewal fee patent year 03 | 12.08.2021 | Renewal fee patent year 04 | 12.08.2021 | Renewal fee patent year 05 | 29.08.2022 | Renewal fee patent year 06 | 28.08.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]US2007213393 (HUNTER WILLIAM L [CA], et al) [A] 1-26 * examples 5, 6 *; | [A]US9364545 (JHAN HUA-JING [TW], et al) [A] 1-26 * example 1 *; | [A]WO2016119308 (UNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY [CN]) [A] 1-26 * claims 1, 2, 7 * * examples 1-2 *; | [A]WO2016123573 (HARVARD COLLEGE [US]) [A] 1-26 * claims 1, 10-21, 24-26, 29-42 ** example 1 *; | [A] - XU KEMING ET AL, "Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-[alpha]2a for liver cancer therapy", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (20130114), vol. 166, no. 3, doi:10.1016/J.JCONREL.2013.01.008, ISSN 0168-3659, pages 203 - 210, XP028994979 [A] 1-26 * abstract * * page 204, column 2, paragraphs 1, 2 * DOI: http://dx.doi.org/10.1016/j.jconrel.2013.01.008 | [A] - HORI Y ET AL, "Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 35, doi:10.1016/J.BIOMATERIALS.2009.08.037, ISSN 0142-9612, (200912), pages 6757 - 6767, (20090919), XP026693729 [A] 1-26 * abstract * DOI: http://dx.doi.org/10.1016/j.biomaterials.2009.08.037 | by applicant | WO2016057265 | WO2018045058 | - SMYTH, M.J. et al., Nature Reviews Clinical Oncology, (20160000), vol. 13, pages 143 - 158 | - BERGE et al., "pharmaceutically acceptable salts", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - BUNDGARD, H., Design of Prodrugs, Elsevier, (19850000), pages 7 - 9,21-24 | - ZHANG et al., Mol. Pharmacol., (20120000), vol. 82, pages 583 - 590 | - WANG et al., ACS Chem. Biol., (20100000), vol. 5, pages 1029 - 1034 | US19960620779 | US19850798385 | US19940303216 | US19970957192 | US19980210114 | US19990361544 | US20000528620 | WO2004US32480 | WO2014US38525 | WO2017US13049 | WO2017US13066 | other | WO02087563 | US2015094518 | - Javeed, A. et al, "Paclitaxel and immune system", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20091105), vol. 38, no. 4, doi:10.1016/j.ejps.2009.08.009, ISSN 0928-0987, pages 283 - 290, XP026691285 DOI: http://dx.doi.org/10.1016/j.ejps.2009.08.009 | - Zeng Qiong-Zhen et al, "Paclitaxel Enhances the Innate Immunity by Promoting NLRP3 Inflammasome Activation in Macrophages", Frontiers in Immunology, vol. 10, no. 72, doi:10.3389/fimmu.2019.00072, pages 1 - 17, XP093038216 DOI: http://dx.doi.org/10.3389/fimmu.2019.00072 | - BYRD-LEIFER CYNTHIA A ET AL, "The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20010801), vol. 31, no. 8, doi:10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N, ISSN 0014-2980, pages 2448 - 2457, XP002199843 DOI: http://dx.doi.org/10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N |